Skip to content
Armando Hasudungan

Overview

Hypermobility Spectrum Disorder (HSD) describes symptomatic joint hypermobility with musculoskeletal (and sometimes systemic) consequences in people who do not meet the 2017 diagnostic criteria for hypermobile Ehlers–Danlos syndrome (hEDS) or another heritable connective-tissue disorder (HCTD). Prevalence of generalised joint hypermobility varies (≈2–35% depending on age/sex/ethnicity and cut-offs), with symptomatic states more common in females and in younger people; many present to primary care, sports, pain and rheumatology settings. 

Definition

Joint hypermobility: increased physiological range of motion compared with age/sex norms; may be localised, peripheral or generalised.
Beighton score: 9-point bedside measure of hypermobility; age-/sex-adjusted thresholds used in 2017 framework (see Table 1)
Hypermobility Spectrum Disorder: symptomatic hypermobility with musculoskeletal complications (e.g., pain, instability, recurrent soft-tissue injuries) that does not satisfy 2017 hEDS or another HCTD diagnosis; subtyped as Generalised-, Peripheral-, Localised-, or Historical-HSD.
Five-part questionnaire (5PQ): historical screen for hypermobility; ≥2 positive answers supports GJH when Beighton is borderline.

Hypermobility Syndromes

What to notice

Detailed image description

Source
Credit
Rights
Article figure
Figure 1 of 1 — 100%

Anatomy & Physiology

 In hypermobility, sensorimotor control often matters more than static laxity—training targets timing, endurance and control rather than “stretching”.

Aetiology & Risk Factors

Aetiology 

Risk factors

Marked skin fragility, atrophic scarring, marfanoid habitus, lens/valvular disease, or aortic pathology should redirect evaluation toward hEDS/EDS subtypes, Marfan or Loeys–Dietz rather than HSD.

Pathophysiology

Load mismatch (capacity < demand) explains many flares—progress load gradually and favour control over range.

Clinical Manifestations

Patients may present with localised symptomatic hypermobility (e.g., affecting one or two joints) or generalised hypermobility with widespread pain and systemic features.

Clinical Examination 

Triad: Hypermobile joints + Activity-related pain/instability + Functional fatigue/deconditioning.

Diagnosis

HDS is based on Beighton score (for joint hypermobility) and exclusion of other connective tissue disorders.

2023 paediatric framework separates paediatric generalised hypermobility and uses age-appropriate assessment, deferring definitive hEDS labelling until biological maturity; symptomatic children are managed with the same principles as HSD.

Differential diagnosis

Marked skin fragility/atrophic scars, aortic root dilatation, lens dislocation, or severe periodontal disease are not typical of HSD—seek genetics/cardiology where present .

Treatment

HSD is not benign joint laxity—it sits on a continuum between physiological flexibility and heritable connective tissue syndromes. Recognition is important because early rehabilitation and lifestyle modifications can reduce long-term pain and disability.

Strength + motor control gains are dose-dependent—consistency trumps intensity; write plans patients can actually keep.

Complications & Prognosis

Complications

 Prognosis

Early, team-based rehab (physio + psychology when needed) outperforms passive care; deprescribe ineffective analgesics.

References

  1. Malfait F, Francomano CA, Byers PH, et al. The 2017 international classification of the Ehlers–Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):8-26.
  2. Castori M, Tinkle B, Levy H, Grahame R, Malfait F, Hakim A. A framework for the classification of joint hypermobility and related conditions. Am J Med Genet C Semin Med Genet. 2017;175(1):148-157.
  3. Tinkle B, Castori M, Berglund B, et al. Hypermobile Ehlers–Danlos syndrome (hEDS) and Hypermobility Spectrum Disorders: clinical description and management. J Multidiscip Healthc. 2017;10:293-312.
  4. Simmonds JV, Keer R, Campbell F, et al. Exercise-based rehabilitation in hypermobility-related disorders: consensus and practical guidance. Curr Treatm Options Rheumatol. 2021;7(4):1-16.
  5. Hakim AJ, Grahame R. A simple questionnaire to detect hypermobility: an adjunct to the Beighton score. J Rheumatol. 2003;30(3): 666-668.
  6. Celletti C, Camerota F, Castori M, et al. Orthostatic intolerance and autonomic dysregulation in hEDS/HSD. Am J Med Genet C Semin Med Genet. 2017;175(1):204-211.
  7. Roma M, Marden CL, De Wandele I, et al. Postural tachycardia syndrome and Ehlers–Danlos hypermobility spectrum disorders: a narrative review. Auton Neurosci. 2018;215:1-8.
  8. Fikree A, Aziz Q, Grahame R. Gastrointestinal manifestations of joint hypermobility-related disorders. Am J Gastroenterol. 2017;112(9):1467-1476.
  9. Barton CJ, Bird ML, Pacey V, et al. Therapeutic exercise for people with generalised joint hypermobility: a systematic review. Arch Phys Med Rehabil. 2022;103(3):566-581.